Leprosy is a granulomatous skin condition which is transmissible. Mycobacterium leprae is the causative agent of this condition. There have been various advancements in the treatment of leprosy to help in preventing deformities and the progression of the condition.
Multidrug therapy is now a widely accepted treatment for leprosy. The dosage is fixed. For children less than 14 years the dosage can be calculated according to age and body weight.
Antibodies and Peptides:
In the in vitro studies of the treatment of leprosy, it has been found that a certain set of antibodies work effectively in the non-activation of the trkA receptors which control and help in preventing the effects of the carriers of leprosy.
A vaccine is also introduced that stimulates an immune response against a peptide component of one of the gene products, and it’s used to treat Mycobacterium disorders like leprosy.
By inhibiting EthR, novel drugs aimed at potentiating antibiotic action activated by the EthA route, in particular ethionamide, are being developed. Its goal was to create a product that was both effective and affordable, with high solubility in fluids, and could be used orally. Its usage as a medication for the treatment of leprosy has been documented.